Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Capital Expenditures (2018 - 2025)

Bicycle Therapeutics' Capital Expenditures history spans 8 years, with the latest figure at $574000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 55.98% year-over-year to $574000.0; the TTM value through Dec 2025 reached $2.4 million, up 90.28%, while the annual FY2025 figure was $2.4 million, 90.28% up from the prior year.
  • Capital Expenditures reached $574000.0 in Q4 2025 per BCYC's latest filing, down from $674000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $9.8 million in Q2 2022 to a low of $12000.0 in Q1 2024.
  • Average Capital Expenditures over 5 years is $1.4 million, with a median of $538000.0 recorded in 2023.
  • Peak YoY movement for Capital Expenditures: soared 5630.41% in 2022, then crashed 99.43% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $1.1 million in 2021, then soared by 35.71% to $1.4 million in 2022, then plummeted by 96.48% to $51000.0 in 2023, then skyrocketed by 621.57% to $368000.0 in 2024, then soared by 55.98% to $574000.0 in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Capital Expenditures are $574000.0 (Q4 2025), $674000.0 (Q3 2025), and $498000.0 (Q2 2025).